Dyne Therapeutics, Inc.
A clinical-stage biotechnology company developing medicines for inherited muscle diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Its FORCE platform delivers RNA-based therapies directly to muscle tissue. Founded in 2017 and incubated by venture firm Atlas Venture, the company takes its name from the "dyne," a unit of force in physics — a fitting nod to its mission of restoring muscle strength.
Sold 1.61M
Sold 2.33M
Sold 8.7K
Sold 3.4K
Sold 521
Sold 9.5K
Bought 16.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kersten DirkDirector · 17 transactions | — | 21.35M | — | — | 1.61M |
| Rhodes Jason PDirector · 63 transactions | -25.5% | 6.81M | — | — | 2.33M |
| Cox JohnCEO & President, Director · 3 transactions | -1.9% | 440.2K | — | — | 8.7K |
| Kerr DouglasChief Medical Officer · 3 transactions | -1.9% | 169.2K | — | — | 3.4K |
| Friedl-Naderer JohannaChief Commercial Officer · 3 transactions | -0.3% | 154.2K | — | — | 521 |
| Lucera ErickChief Financial Officer · 3 transactions | -7.3% | 121.6K | — | — | 9.5K |
| Posner Brian SDirector · 7 transactions | +188.2% | 24.5K | — | 16.0K | — |
| Lubner David CharlesDirector · 1 transaction | -100% | 0 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -3.95M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.